Congo, Democratic Republic of the vs Gabon: Access to anti-retroviral drugs, male
Congo, Democratic Republic of the
75.0%
in 2024
Gabon
74.0%
in 2024
Congo, Democratic Republic of the rank
55th
Gabon rank
58th
Access to anti-retroviral drugs, male over time
- Congo, Democratic Republic of the
- Gabon
How they compare
Congo, Democratic Republic of the currently reports 75.0% against 74.0% in Gabon, a difference of 1.0%.
The two have swapped places 1 time across 25 shared years of data; in 2000 it was Gabon ahead.
Congo, Democratic Republic of the ranks 55th and Gabon ranks 58th of 141 countries.
Across the 3 decades both report, Congo, Democratic Republic of the averaged higher in 1 and Gabon in 2.
Head to head by decade
| Decade | Congo, Democratic Republic of the | Gabon | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 1.9% | 13.3% | 11.4% | Gabon |
| 2010s | 19.5% | 43.6% | 24.1% | Gabon |
| 2020s | 68.0% | 59.8% | 8.2% | Congo, Democratic Republic of the |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, Congo, Democratic Republic of the or Gabon?
- Congo, Democratic Republic of the, at 75.0% against 74.0% in Gabon as of 2024.
- What is the difference in access to anti-retroviral drugs, male between Congo, Democratic Republic of the and Gabon?
- 1.0%, with Congo, Democratic Republic of the ahead.
- How many years of comparable data are there for Congo, Democratic Republic of the and Gabon?
- 25 years are reported by both, from 2000 to 2024.
- How do Congo, Democratic Republic of the and Gabon rank globally for access to anti-retroviral drugs, male?
- Congo, Democratic Republic of the ranks 55th and Gabon ranks 58th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.